Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DX9T0N
|
|||
| Drug Name |
AZD8701
|
|||
| Synonyms |
ION736
Click to Show/Hide
|
|||
| Drug Type |
Antisense oligonucleotide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
AstraZeneca; Ionis Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | FOXP3 messenger RNA (FOXP3 mRNA) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04504669) First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.